

# WDNA WisdomTree BioRevolution UCITS ETF - USD Acc

## Investment Objective

The WisdomTree BioRevolution UCITS ETF (the "Fund") seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution ESG Screened Index (the "Index").

## Index Description

The index is designed to track performance of companies that will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines). The index excludes companies which do not meet WisdomTree's ESG (environmental, social and governance) criteria. To be included in the Index, companies must meet certain risk management criteria, as well as minimum liquidity requirements, WisdomTree's ESG screen and be involved in BioRevolution activities. The key sectors listed below are used as guidelines to determine if a company is primarily involved in BioRevolution Activities, including Human health, Agriculture & Food, Materials, Chemicals, & Energy and Biological Machines & Interfaces.

The Index is rebalanced on a semi-annual basis.

## Performance (Net of fees) (USD)

| Name                                                   | QTR    | YTD    | 1-Year | 3-Year | Inception Date |
|--------------------------------------------------------|--------|--------|--------|--------|----------------|
| WDNA NAV                                               | 25.77% | 36.99% | 69.44% | 13.69% | 1.53%          |
| WisdomTree BioRevolution ESG Screened Net Return Index | 25.85% | 37.28% | 69.98% | 14.04% | 1.85%          |

**Source: WisdomTree UK, Bloomberg, as of 31/08/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.**

## Product Information

|                        |                                                                |
|------------------------|----------------------------------------------------------------|
| Asset Class            | Equities                                                       |
| Benchmark              | WisdomTree BioRevolution ESG Screened Net Return Index         |
| Replication Method     | Physical, Fully Replicated                                     |
| Total Expense Ratio    | 0.45%                                                          |
| Base Currency          | USD                                                            |
| Use of Income          | Accumulating                                                   |
| Distribution Frequency | N/A                                                            |
| Inception Date         | 06/12/2021                                                     |
| Financial Year End     | 31 December                                                    |
| UCITS Compliant        | Yes                                                            |
| ISA Eligible           | Yes                                                            |
| SIPP Eligible          | Yes                                                            |
| PEA Eligible           | No                                                             |
| Registration           | AT, CH, DE, DK, ES, FI, FR, GB, IE, IT, LU, NL, NO, SE         |
| Manager                | WisdomTree Management Ltd.                                     |
| Investment Manager     | Keyridge Asset Management Limited                              |
| Administrator          | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Custodian              | The Bank of New York Mellon SA/NV, Dublin Branch               |

## Index Information

|                      |                                                        |
|----------------------|--------------------------------------------------------|
| Index                | WisdomTree BioRevolution ESG Screened Net Return Index |
| Index Provider       | WisdomTree, Inc.                                       |
| Index Currency       | USD                                                    |
| Index Bloomberg Code | WTEDNAN                                                |

## ESG Characteristics

|                 |                |
|-----------------|----------------|
| SFDR Disclosure | SFDR Article 8 |
|-----------------|----------------|

## Calendar Year Performance (Net of fees)

| Name                                                   | 2022    | 2023   | 2024    | 2025   |
|--------------------------------------------------------|---------|--------|---------|--------|
| WisdomTree BioRevolution UCITS ETF - USD Acc           | -26.03% | -2.73% | -14.21% | 22.34% |
| WisdomTree BioRevolution ESG Screened Net Return Index | -25.80% | -2.38% | -13.95% | 22.73% |


Source: WisdomTree UK, Bloomberg, as of 31/08/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.

## Rolling 12-month performance (Net of fees)

| Name                                                   | Aug'2022-Aug'2023 | Aug'2023-Aug'2024 | Aug'2024-Aug'2025 | Aug'2025-Aug'2026 |
|--------------------------------------------------------|-------------------|-------------------|-------------------|-------------------|
| WisdomTree BioRevolution UCITS ETF - USD Acc           | -9.24%            | 2.48%             | -15.38%           | 69.44%            |
| WisdomTree BioRevolution ESG Screened Net Return Index | -8.93%            | 2.83%             | -15.14%           | 69.98%            |

Source: WisdomTree UK, Bloomberg, as of 31/08/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.

| Top 10 Holdings (% Weight) |       |
|----------------------------|-------|
| Moderna Inc                | 7.53% |
| Twist Bioscience Corp      | 7.26% |
| Eli Lilly & Co             | 3.56% |
| Johnson & Johnson          | 2.79% |
| 10X Genomics Inc-Class A   | 2.66% |
| Immunome Inc               | 2.64% |
| Natera Inc                 | 2.49% |
| Tempus Ai Inc              | 2.24% |
| United Therapeutics Corp   | 2.12% |
| Darling Ingredients Inc    | 2.12% |



| Top 10 Countries (% Weight) |        |
|-----------------------------|--------|
| United States               | 86.68% |
| Germany                     | 2.93%  |
| Switzerland                 | 2.79%  |
| Netherlands                 | 2.31%  |
| United Kingdom              | 2.19%  |
| Denmark                     | 1.87%  |
| Belgium                     | 0.69%  |
| Australia                   | 0.54%  |

NB: Sources for all tables/charts on these pages: WisdomTree UK, Bloomberg. All data as of 31/08/2026

Listing Information

| Exchange       | Trading Currency | Exchange Ticker | Bloomberg Code | RIC      | SEDOL   | ISIN         | WKN    | Listing Date |
|----------------|------------------|-----------------|----------------|----------|---------|--------------|--------|--------------|
| LSE            | USD              | WDNA            | WDNA LN        | WDNA.L   | BMH8657 | IE000O8KMPM1 | A3CY21 | 09/12/2021   |
| LSE            | GBx              | WBIO            | WBIO LN        | WTWBIO.L | BMH8668 | IE000O8KMPM1 | A3CY21 | 09/12/2021   |
| Xetra          | EUR              | WRNA            | WRNA GY        | WRNA.DE  | BMH8679 | IE000O8KMPM1 | A3CY21 | 09/12/2021   |
| Borsa Italiana | EUR              | WDNA            | WDNA IM        | WDNA.MI  | BMH8680 | IE000O8KMPM1 | A3CY21 | 17/01/2022   |
| BMV            | MXN              | WDNA1           | WDNA1N MM      | WDNA.MX  | BMDKSY0 | IE000O8KMPM1 | A3CY21 | 26/12/2022   |
| SIX            | USD              | WDNA            | WDNA SW        | WDNA.S   | BPZK4H4 | IE000O8KMPM1 | A3CY21 | 23/01/2023   |

## Potential Benefits

The Fund offers access through direct investment in publicly listed companies, which will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines).

Focused exposure to businesses that have multi-sector genetics and biotechnology investments with strong growth characteristics and which meet WisdomTree's ESG (environmental, social and governance) criteria.

The research for the selection of companies in the Index and, subsequently, the Fund, is conducted by expert in the BioRevolution space, ensuring the portfolio remains focused and relevant.

The ETF is physically backed and UCITS compliant.

## Potential Risks

Although the Index was created to select companies with a relatively higher exposure to BioRevolution activities, there is no guarantee this objective will be achieved.

An investment in equities may experience high volatility and should be considered as a long-term investment.

Higher growth companies such as those that play a part in megatrends tend to trade at higher valuations. The investor should consider the risk that comes with higher valuations as part of any investment decision.

Investment risk may be concentrated in specific sectors, countries, companies or currencies.

This list does not cover all risks-further risks are disclosed in the KID/KIID and Prospectus.

## Glossary

**Dividend Weighted Index:** an index that determines the weight of its constituents using the dividends paid by the security rather than another variable (the most common is Market Cap weighted indices).

**Fully Replicated:** assets are invested in securities that match the constituents of the relevant index, in the same proportion.

**Fundamentally Weighted Index:** an index that weights securities on the basis of factors such as dividends or earnings.

**Large Cap, Mid Cap and Small Cap:** refers to market capitalisation and is calculated by multiplying the price of a stock by the number of shares outstanding.

**Listing currency:** the trading currency on the exchange.

**Physical (Optimised):** assets are predominantly invested in securities that are constituents of the index, but may also hold securities whose characteristics closely resemble the characteristics of the index.

**Physically Backed:** securities held by the fund are the actual securities not a derivative.

**Rebalance:** An index is created by applying a certain set of selection and weighting rules of countries, sectors and stocks at a certain frequency. A Rebalance is when WisdomTree re-applies its rules based selection and weighting process.

**Rebalance Frequency:** The frequency by which the constituents of the index are screened and their weights changed.

**Replication Method:** the method by which the fund gets exposure to the benchmark index.

**Share class currency or the "NAV currency":** The currency that the fund's NAV is issued in.

**Total Expense Ratio (TER):** A measure of the total costs associated with managing and operating a fund. The TER consists primarily of management fees plus other expenses such as trustee, custody and operating expenses. It does not cover the swap fee. The TER is expressed as a percentage of the fund's total net asset value.

# Disclaimer

## IMPORTANT INFORMATION

**Marketing communications issued in the European Economic Area (“EEA”):** This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

**Marketing communications issued in jurisdictions outside of the EEA:** This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

**This marketing communication is intended for all investors; however, the WisdomTree products described in this document and related materials may be restricted in certain jurisdictions and may only be available to particular categories of investors in accordance with applicable laws and regulations. Where a product is not authorised or its distribution is restricted in your jurisdiction, it is the responsibility of any person or entity in possession of this information to inform themselves of, and comply with, all relevant restrictions. Before making any investment, investors should seek appropriate legal, regulatory, tax and investment advice to assess the suitability and implications of investing in these products. Information about WisdomTree products is available at [wisdomtree.eu](https://www.wisdomtree.eu). WisdomTree does not offer investment advice tailored to individual circumstances. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.**

An investment in exchange-traded products (“ETPs”) is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

Certain funds referred to in this document are issued by WisdomTree Issuer ICAV (“WT Issuer”). WT Issuer is an open-ended, umbrella-type Irish Collective Asset-management Vehicle with segregated liability between sub-funds and is authorised by the Central Bank of Ireland (“CBI”) as an Undertaking for Collective Investment in Transferable Securities (“UCITS”) under Irish law. Each fund is represented by a separate class of shares (the “Shares”) issued by WT Issuer.

The Fund is described in a Key Information Document (KID) or Key Investor Information Document (KIID) for UK investors, and the prospectus of WT Issuer (“WT Prospectus”). A copy of the WT Prospectus and the KID / KIID is available, for EEA/UK only, in English at [www.wisdomtree.eu](https://www.wisdomtree.eu). Where required under national rules, the KID will also be available in the local language of the relevant EEA Member State. Investors should read the WT Prospectus before investing and should refer to the section of the WT Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the Shares.

The summary of investor rights (<https://www.wisdomtree.eu/-/media/eu-media-files/other-documents/regulatory/summary-of-investor-rights---wisdomtree-issuer-icav.pdf>) associated with an investment in the fund is available in English on WisdomTree Europe’s website. WisdomTree Management Limited may decide to terminate the arrangements made for the marketing of its collective investment undertakings. In such circumstances, shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the fund free of any charges or deductions for at least 30 working days from the date of such notification.

French Investors should note that, relative to the expectations of the Autorité des Marchés Financiers, this Fund presents disproportionate communication on the consideration of non-financial criteria in its investment policy.

This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements (<https://www.fca.org.uk/consumers/sustainable-investment-labels-greenwashing>).

## Additional Information

**For Investors in Switzerland:** This document constitutes an advertisement of the financial product(s) mentioned herein.

The prospectus (in English only) and the key investor information documents (KID) (in German, French and Italian) are available from WisdomTree's website: <https://www.wisdomtree.eu/en-ch/resource-library/prospectus-and-regulatory-reports>

**For WisdomTree UCITS products only:** the representative and paying agent of the ETPs in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent. Some of the sub-funds referred to in this document may not have been registered with the Swiss Financial Market Supervisory Authority ("FINMA"). In Switzerland, such sub-funds that have not been registered with FINMA may only be available to Qualified Investors.

**For Investors in France:**

The information in this document is intended exclusively for professional investors (as defined under the MiFID) investing for their own account and this material may not in any way be distributed to the public. The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Financial Regulatory as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, the Key Investor Information Document, any supplements or addenda thereto, the latest annual reports and the memorandum of incorporation and articles of association) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.